UPDATE Thursday, April 21, 2022, 5:00 p.m. EDT—AbbVie issued this statement: AbbVie supports the 340B program and is committed to the program’s goal of improving access to medicines for uninsured and vulnerable patients. Our 340B initiative does not block access to 340B priced medicines for any covered entity of the 340B program and—critically—patients will continue to have uninterrupted access to AbbVie’s medicines. Additionally, our initiative does not affect federal grantee covered entities, such as community health centers, federally-qualified health centers and Ryan White clinics.
Six groups that support patients with HIV/AIDS and viral hepatitis and their caregivers issued a joint statement yesterday criticizing drug manufacturers AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.
Six groups that support patients with HIV/AIDS and viral hepatitis and their caregivers issued a joint statement yesterday criticizing drug manufacturers AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
